Skip to content

In the BioHarmony Drug Report Database

Reteplase

Retavase, Rapilysin (reteplase) is an enzyme pharmaceutical. Reteplase was first approved as Retavase on 1996-08-29. It is used to treat myocardial infarction and ventricular dysfunction in the USA. It has been approved in Europe to treat myocardial infarction.
Trade Name Rapilysin
Common Name Reteplase
Indication myocardial infarction, ventricular dysfunction
Drug Class Enzymes: tissue-type plasminogen activators
Reteplase
Get full access now